

Anti-androgen therapies

Drug	Enzyme substrate	Active metabolite	Enzymes induction	Enzymes inhibition	Drug-drug interaction	BBB crossing	Potency	Effect of point mutations (F876L, W741L, T877A)
Flutamide 1st Gen	CYP3A4, 1A2	Yes (higher)	CYP1A2	//	Inducers: minimal effect	Yes	700 nM	Resistance
					Inhibitors: minimal effect			
Bicalutamide 1st Gen	CYP3A4	No	//	CYP3A4, 2D6, 2C9, 2C19	Inducers: reduced efficacy	Yes	160 nM	Resistance
					Inhibitors: increased toxicity			
Abiraterone 2nd Gen	CYP3A4	No	//	CYP1A2, 2C8, 2D6, 2C9, 2C19	Inducers: reduced efficacy	Yes	//	Resistance
					Inhibitors: increased toxicity			
Enzalutamide 2nd Gen	CYP2C8	No	CYP3A4, 2D6, 2C9, 2C19	//	Inducers: reduced efficacy	Yes	86 nM	Resistance
					Inhibitors: increased toxicity			
Apalutamide 2nd Gen	CYP2C8, 3A4	Yes (1/3)	CYP3A4, 2D6, 2C9, 2C19	//	Inducers: reduced efficacy	Yes	93 nM	Resistance
					Inhibitors: increased toxicity			
Darolutamide 3rd Gen	CYP3A4	Yes (equal)	//	BCRP, P-gp, OATP1B1, 1B3	Inducers: null effect	No	11 nM	No
					Inhibitors: null effect			